A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager." This type of immunotherapy ignites our own ...
Kennedy researchers have uncovered key design parameters for bispecific T-cell engagers (TcEs)—a class of cancer immunotherapy drugs. The findings may help unlock the full potential of TcEs and ...
The field of lupus research continues to advance, bringing forward innovative approaches aimed at improving outcomes for people living with the disease. In this recording from our recent virtual ...
EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and ...
In this JCO Article Insights episode, Dr. Ece Cal interviews Dr. Martin Wermke, author of the JCO article, "Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager ...
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic ...
(RTTNews) - HCW Biologics Inc. (HCWB) announced Friday positive pre-clinical results for its multi-specific T-cell engagers targeting solid tumors, including pancreatic cancer, using its proprietary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results